- Home
- ZIP vs AVBP Comparison
ZIP vs AVBP Comparison
Compare ZIP & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- AVBP
- Stock Information
- Founded
- ZIP 2010
- AVBP 2021
- Country
- ZIP United States
- AVBP United States
- Employees
- ZIP N/A
- AVBP N/A
- Industry
- ZIP Diversified Commercial Services
- AVBP
- Sector
- ZIP Consumer Discretionary
- AVBP
- Exchange
- ZIP Nasdaq
- AVBP NYSE
- Market Cap
- ZIP 460.8M
- AVBP 862.8M
- IPO Year
- ZIP 2021
- AVBP 2024
- Fundamental
- Price
- ZIP $5.29
- AVBP $20.77
- Analyst Decision
- ZIP Hold
- AVBP Strong Buy
- Analyst Count
- ZIP 5
- AVBP 8
- Target Price
- ZIP $7.40
- AVBP $39.00
- AVG Volume (30 Days)
- ZIP 978.9K
- AVBP 498.9K
- Earning Date
- ZIP 08-06-2025
- AVBP 08-13-2025
- Dividend Yield
- ZIP N/A
- AVBP N/A
- EPS Growth
- ZIP N/A
- AVBP N/A
- EPS
- ZIP N/A
- AVBP N/A
- Revenue
- ZIP $461,827,000.00
- AVBP N/A
- Revenue This Year
- ZIP N/A
- AVBP $85.82
- Revenue Next Year
- ZIP $11.97
- AVBP N/A
- P/E Ratio
- ZIP N/A
- AVBP N/A
- Revenue Growth
- ZIP N/A
- AVBP N/A
- 52 Week Low
- ZIP $4.25
- AVBP $15.47
- 52 Week High
- ZIP $11.25
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- ZIP 48.61
- AVBP 39.60
- Support Level
- ZIP $4.59
- AVBP $20.00
- Resistance Level
- ZIP $5.51
- AVBP $23.27
- Average True Range (ATR)
- ZIP 0.32
- AVBP 1.51
- MACD
- ZIP 0.00
- AVBP -0.49
- Stochastic Oscillator
- ZIP 60.28
- AVBP 13.28
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.